References
- AldersonPOComputed tomography, ultrasound, and scintigraphy of the liver in patients with colon or breast carcinoma: a prospective comparisonRadiology198314922523010.1148/radiology.149.1.6611929
- BrunetonJNEtiologic diagnosis of hepatic lesions in cancer patients. Value of ultrasound and liver function testsClin Imaging19972136637110.1016/S0899-7071(97)00043-0
- CiattoSStaging breast cancer–screening for occult metastasesTumori1985714339344
- D'AlessandroRSerum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancerBreast Cancer Res Treat20016891910.1023/A:1017903724176
- de BrauwLMHepatic metastases: comparative study of diagnostic ultrasound, CT, nuclear scintigraphy and laboratory testsNeth J Surg1991439294
- de BrauwLMProspective comparative study of ultrasound, CT-scan, scintigraphy and laboratory tests to detect hepatic metastasesJ Nucl Biol Med199135131134
- del Rocio Estrada-SanchezGMireles EnriquezMValverde CastanedaNReliability of CA 15-3 in the follow up of female patients with breast carcinoma and bone metastasesRev Invest Clin200355412418
- DoneganWLSprattJSCancer of the Breast2002
- DowieJ‘Evidence-based', ‘cost-effective' and ‘preference-driven' medicine: decision analysis based medical decision making is the pre-requisiteJ Health Serv Res Policy19961104113
- EngelhardKComparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancerEur Radiol2004149910510.1007/s00330-003-1968-7
- FisherBTwenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancerN Engl J Med2002347161233124110.1056/NEJMoa022152
- FisherBTamoxifen, radiation therapy or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or lessJ Clin Oncol2002204141414910.1200/JCO.2002.11.101
- ForrestAPRandomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast GroupLancet1996348902970871310.1016/S0140-6736(96)02133-2
- GallowitschHJF-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imagingInvest Radiol200338250256
- GuadagniFA re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal studyClin Cancer Res2001723572362
- HeltonJCDavisFJIllustration of sampling-based methods for uncertainty and sensitivity analysisRisk Anal20022259162210.1111/0272-4332.00041
- HouMFEvaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancerKaohsiung J Med Sci199915520528
- HuninkMDeciding when to testDecision Making in Health and Medicine, Integrating Evidence and Values2001157176
- KarmenCMeasurement of biliary alkaline phosphatase by mini-column chromatography and by electrophoresis and its application to the detection of liver metastases in patients with breast cancerJ Clin Pathol19843721221710.1136/jcp.37.2.212
- KimNKValue of alkaline phosphatase, 5′-nucleotidase, gamma-glutamyltransferase, and glutamate dehydrogenase activity measurements (single and combined) in serum in diagnosis of metastasis to the liverClin Chem19772320342038
- KokkoRHakamaMHolliKRole of chest X-ray in diagnosis of the first breast cancer relapse: a randomized trialBreast Cancer Res Treat200381333910.1023/A:1025419114857
- KronzJDWestraWHEpsteinJIMandatory second opinion surgical pathology at a large referral hospitalCancer199986112426243510.1002/(SICI)1097-0142(19991201)86:11<2426::AID-CNCR34>3.0.CO;2-3
- LacicMBone marrow immunoscintigraphy for the detection of skeletal metastases in patients with breast cancerNucl Med Commun19992013514310.1097/00006231-199902000-00005
- LauroSComparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patientsAnticancer Res19991935113515
- LeeRCWrightWEDevelopment of human exposure factor distributions using maximum-entropy inferenceJ Expos Anal Environ Epi19944329341
- McGarrityTJSamuelsTWilsonFAAn analysis of imaging studies and liver function tests to detect hepatic neoplasiaDigest Dis Sci198732101113111710.1007/BF01300197
- MorganMGHenrionMUncertainty: A Guide to Dealing with Uncertainty in Quantitative Risk and Policy Analysis1990
- OhtaMWhole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphyNucl Med Commun20012287587910.1097/00006231-200108000-00005
- ParmigianiGMeasuring uncertainty in complex decision analysis modelsStat Methods Med Res20021151353710.1191/0962280202sm307ra
- PriorJOThe value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancerNucl Med Commun2003241293610.1097/00006231-200301000-00012
- RavaioliAStaging of breast cancer: new recommended standard procedureBreast Cancer Res Treat200272536010.1023/A:1014900600815
- RealeMGSkeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancerInt J Biol Markers1995104246
- RitzkeCAlkaline phosphatase isoenzymes in detection and follow up of breast cancer metastasesAnticancer Res19981812431249
- RussellSNorvigPUncertainty. Artificial Intelligence: A Modern Approach1995
- SchattevoetWHCorstensFHBeexLARosenbuschGJReliability of sonography in diagnosing liver metastases in breast and bronchial cancer. A retrospective comparison of physical examination, laboratory tests and liver scintigraphyUltraschall Med1986729329910.1055/s-2007-1013970
- SpanuAThe role of (99m)Tc-tetrofosmin pinhole-SPECT in breast cancer non palpable axillary lymph node metastases detectionQ J Nucl Med200347116128
- StaradubVLChanges in breast cancer therapy because of pathology second opinionsAnn Surgical Oncol200291098298710.1007/BF02574516
- TemperoMAWilliamsCAAndersonJCThe value of hepatic ultrasound and biochemical liver tests in screening for liver metastasesJ Clin Oncol1986410741078
- TorresMCA 549 and SP2 in postoperative breast cancer patients. Comparison with CA 15.3, CEA and TPAInt J Biol Markers1995109499
- VizcarraEValue of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasisBreast Cancer Res Treat19963720921610.1007/BF01806502
- WaalkesTPBiological markers as an aid in the clinical management of patients with liver metastasesJ Surg Oncol198220839410.1002/jso.2930200205
- WeinsteinMCClinical Decision Analysis1980
- WojtackiJElevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 casesPrzegl Lek200158498503